Detailed description of the adverse reactions and treatment methods of Pazopanib (Victor)

1. Overview of Drugs

Pazopanib (trade name Votrient) is an oral small molecule tyrosine kinase inhibitor (TKI) that mainly targets VEGFR, PDGFR, c-KIT and other signaling pathways. It is widely used to treat advanced renal cell carcinoma (RCC) and some soft tissue sarcomas (STS). As an anti-angiogenesis targeted drug, pazopanib can significantly delay tumor growth, but its mechanism of action may also lead to multi-system adverse reactions. Therefore, understanding its potential adverse reactions and countermeasures is crucial for safe clinical use of drugs and improving patients' quality of life.

2. Classification and manifestations of main adverse reactions

1.Gastrointestinal reactions

The most common ones include Diarrhea, nausea, vomiting, loss of appetite and stomatitis. Some patients may experience abdominal pain or indigestion. It usually appears in the early stages of medication and can lead to weight loss and malnutrition.

2.Abnormal liver function

Pazopanib may cause an increase in serum aminotransferases (ALT/AST) and bilirubin, and in severe cases, liver damage may occur. Liver function abnormalities usually develop during the first few weeks of treatment and require close monitoring.

3.Adverse reactions to cardiovascular and blood systems

Includes Hypertension, arrhythmia, fatigue, thrombocytopenia and anemia. Hypertension is the most common cardiovascular event, and some patients may experience headache, dizziness, or edema. Hematological abnormalities can increase the risk of infection, bleeding, and fatigue.

4.Skin and hair reactions

Patients often experience hand-foot syndrome, rashes, hair loss, and brittle or discolored nails. Hand-foot syndrome. Although not life-threatening, it can affect patient quality of life and may require dosage or topical care adjustments.

5.Other adverse reactions

Including Proteinuria, thyroid dysfunction, fatigue and mild bleeding. Some patients may experience muscle or joint pain, and occasionally, but less frequently, interstitial lung disease or pulmonary fibrosis.

3. How to deal with adverse reactions

1. Management of gastrointestinal reactions

Mild to moderate diarrhea or nausea: Oral rehydration solutions, antidiarrheal drugs (such as loperamide), or antiemetics (such as ondansetron) may be used.

Severe cases: If necessary, temporarily stop the medication or reduce the dose, and adjust your diet at the same time, eat small amounts more often, and avoid greasy and irritating foods.

2.Treatment of abnormal liver function

Regularly monitorALT, AST, and total bilirubin levels.

Mild elevation (≤3 times normal value): Continue to observe and supplement with liver protection drugs.

Moderate or severe increase (>5 times the normal value): The drug needs to be stopped, and the dose reduction and reuse can be considered after the liver function returns to a safe range.

3.Cardiovascular and blood system management

Patients with hypertension need to monitor their blood pressure and use antihypertensive drugs as directed by their doctor.

Patients with hematological abnormalities should have their blood routine monitored. If the anemia is severe, blood transfusion or iron therapy may be considered.

If symptoms of arrhythmia or heart failure occur, seek medical attention immediately and discontinue medication if necessary.

4.Skin and hair reaction management

Hand-foot syndrome can be relieved by applying local cold compresses, moisturizing, and avoiding friction and irritating activities.

For rashes or hair loss, use mild skin care products and masking measures, and adjust medication dosage if necessary.

5.Management of other adverse reactions

Patients with proteinuria need to check their urine routine regularly and adjust the dosage or discontinue the drug if necessary.

Patients with thyroid dysfunction can receive supplementary treatment based on thyroid hormone levels.

For muscle or joint pain, symptomatic analgesics and moderate exercise can be given.

4. Clinical precautions and safe medication recommendations

1.Dose adjustment

Based on the severity of adverse reactions, strategies for pazopanib may be adopted: Temporary discontinuation, dose reduction or extended dosing interval . The initial dose is usually800mgonce a day, but if the patient has poor tolerance, it can be reduced to 600mg or 400mg.

2.Regular monitoring

Liver function, blood pressure, blood routine, thyroid function and urine routine are must-check items.

ECG and cardiac function monitoring can be performed selectively based on the patient's medical history.

3.Patient education

Patients should understand common adverse reactions, return for follow-up visits on time, and record changes in symptoms. Avoid adjusting the dosage or stopping the medication on your own, and pay attention to lifestyle adjustments, such as low-salt diet, regular rest and moderate exercise.

4.Be careful when using combined medications

Pazopanib should not be used simultaneously with potentCYP3A4 inhibitors or inducers to avoid affecting blood concentration and toxicity. Other medications such as anticoagulants, antihypertensives, and diuretics require careful monitoring.

Pazopanib, as an anti-tumor targeted drug, has shown significant efficacy in advanced RCC and soft tissue sarcoma, but its multi-system adverse reactions cannot be ignored. Through regular monitoring, dose adjustment, symptomatic treatment and patient education, the risk of toxicity can be reduced to the greatest extent and the patient's quality of life and treatment compliance can be improved. Mastering these coping methods is crucial for safe clinical medication use and optimizing efficacy.

Reference link:https://www.drugs.com